[Prevention of fungal infections in children and adolescents with cancer]
- PMID: 11577364
- DOI: 10.1055/s-2001-17502
[Prevention of fungal infections in children and adolescents with cancer]
Abstract
Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia. The incidence of invasive fungal infections in these settings may range from 10 to 25 % despite empirical antifungal therapy with an overall case fatality rate of up to 50 and 75 % depending on the organism. Preventive interventions are thus warranted, including but not limited to chemoprophylaxis with antifungal agents. Effective chemoprophylaxis of invasive Candida infections with a long-term benefit for overall survival has been demonstrated in patients with allogeneic bone marrow transplantation. However, its benefit in other high-risk populations is less well established, and a clearly effective approach to chemoprophylaxis for invasive Aspergillus infections has not been documented in appropriately designed clinical trials. This article reviews epidemiology and current approaches to chemoprophylaxis of opportunistic invasive fungal infections in children and adolescents with cancer and/or stem cell transplantation, and provides evidence-based guidelines for indications and modalities of antifungal prophylaxis and antifungal infection control measures in this population.
Similar articles
-
Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.Haematologica. 1997 May-Jun;82(3):297-304. Haematologica. 1997. PMID: 9234575 Review.
-
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23-i32. doi: 10.1093/jac/dki221. J Antimicrob Chemother. 2005. PMID: 16120631 Review.
-
Evolving concepts of prevention and treatment of invasive fungal infections in pediatric bone marrow transplant recipients.Bone Marrow Transplant. 1996 Dec;18 Suppl 3:S15-20. Bone Marrow Transplant. 1996. PMID: 8971401 Review.
-
Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients.Pharmacotherapy. 1998 May-Jun;18(3):549-64. Pharmacotherapy. 1998. PMID: 9620106 Review.
-
Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation.Am J Hematol. 2002 Dec;71(4):260-7. doi: 10.1002/ajh.10234. Am J Hematol. 2002. PMID: 12447954 Clinical Trial.
Cited by
-
Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.BMC Infect Dis. 2012 Oct 19;12:263. doi: 10.1186/1471-2334-12-263. BMC Infect Dis. 2012. PMID: 23082876 Free PMC article.
-
[Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Apr;53(4):357-88. doi: 10.1007/s00103-010-1028-9. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010. PMID: 20300719 Free PMC article. German. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
